Luna Diabetes provides automated insulin delivery specifically designed for individuals using insulin pens during sleep. This system uses micro-boluses to maintain optimal glucose control overnight without requiring a traditional insulin pump. The technology allows users to maintain their existing Multiple Daily Injection (MDI) regimen while achieving worry-free nighttime glucose management.
Funding
$23.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
People who manage diabetes with multiple daily insulin injections often experience unstable glucose levels during sleep, leading to nocturnal hyper‑ or hypoglycemia. Existing insulin pumps are bulky, require continuous wear, and are not widely adopted by pen users, leaving a gap in safe, automated nighttime insulin delivery.
Solution
Luna provides an automated insulin delivery (AID) system designed exclusively for nighttime use by insulin‑pen users. The device connects to a compatible continuous glucose monitor (CGM) and, based on real‑time glucose data, delivers micro‑boluses of rapid‑acting insulin throughout the night. Users set their total daily basal dose once via a smartphone app; the algorithm then autonomously adjusts dosing while they sleep, eliminating the need for a pump during waking hours. Luna’s compact, patch‑pump form factor is worn only while in bed, preserving daytime freedom and routine. Integrated safety modules monitor glucose trends and insulin flow to prevent over‑delivery or occlusions, and all data are encrypted and can be streamed to cloud analytics or electronic health records for clinician review.
Target Audience
Primary users are adults (18 +) with Type 1 diabetes who manage their condition with multiple daily insulin injections and a CGM. The solution is also intended for endocrinologists, diabetes educators, and other healthcare providers prescribing insulin therapy.
Features
- Closed‑loop algorithm that continuously reads CGM data and issues micro‑bolus insulin deliveries during sleep.
- One‑time basal‑dose entry via mobile app; no daily basal‑rate programming or carb‑ratio settings required.
- World’s smallest patch‑pump design, worn only at night, with no tubing or 24/7 attachment.
- Direct fill capability from standard rapid‑acting insulin pens, reducing fill time by up to 80 %.
- Drift Detection™ and Occlusion Detection safety layers that suspend insulin delivery when glucose is falling or flow is interrupted.
- HIPAA‑compliant, end‑to‑end encrypted data transmission; optional FHIR‑compatible API for EMR integration.
- In‑app training, real‑time alerts, and remote device diagnostics accessible to both patients and providers.